Short Interest in CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Rises By 82.3%

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 394,744 shares, a growth of 82.3% from the June 15th total of 216,478 shares. Based on an average trading volume of 1,137,720 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s stock are sold short.

CSL Stock Up 1.5%

Shares of OTCMKTS:CSLLY opened at $21.76 on Friday. The company’s 50-day moving average is $18.99 and its 200 day moving average is $33.12. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. CSL has a fifty-two week low of $16.01 and a fifty-two week high of $44.85.

Wall Street Analysts Forecast Growth

CSLLY has been the subject of a number of analyst reports. Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Zacks Research downgraded CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.